Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACAM3000 MVA Vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | MVA3000 Smallpox vaccine (1x10-8) with Dryvax Challenge at Day 112 |
| B | EXPERIMENTAL | MVA3000 Smallpox vaccine (1x10-8) with no Challenge |
| C | PLACEBO_COMPARATOR | Placebo |
| D | EXPERIMENTAL | MVA3000 Smallpox vaccine (1x10-7) with Dryvax challenge at Day 112 |
| E | EXPERIMENTAL | MVA3000 Smallpox vaccine (1x10-6) with Dryvax challenge at Day 112 |
| Name | Type | Description |
|---|---|---|
| ACAM3000 MVA Vaccine | BIOLOGICAL | Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days |
Inclusion Criteria: Subjects must meet the following to be eligible for the study: * adult males or females who provided informed consent for the study. * adults 18 and 31 years (inclusive). * good general health, * female subjects must not be pregnant or lactating and be on appropriate contracept...
ACAM3000 MVA Vaccine is an investigational vaccine being studied for the prevention of smallpox. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
ACAM3000 MVA Vaccine is being developed by Sanofi, a company listed on the stock exchange under the ticker symbol SNY. The vaccine is in Phase 1 clinical trials for smallpox.
ACAM3000 MVA Vaccine is in Phase 1 clinical development. It is an investigational vaccine and has not been approved for use. One Phase 1 trial has been completed.
ACAM3000 MVA Vaccine has one completed Phase 1 trial, NCT00079820, which evaluated its safety, tolerability, and immune response in 110 healthy adult volunteers in the United States. The trial was randomized, double-blind, and placebo-controlled.
No, ACAM3000 MVA Vaccine is a vaccine, not a monoclonal antibody. It is being developed for the prevention of smallpox and is currently in Phase 1 clinical trials.